



Vaccination Progress in COVID-19 and HPV

Guest Editor:

Dr. Wangnan Cao

Department of Social Medicine
and Health Education, School of
Public Health, Peking University
Health Science Center, Beijing
100191, China

Deadline for manuscript
submissions:

30 April 2024

Message from the Guest Editor

Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for curbing the COVID-19 pandemic. Over a year into the biggest vaccination campaign in history, more than 12.7 billion doses have been administered across 184 countries. The human papillomavirus (HPV) vaccine helps to protect against cancers caused by HPV, including **cervical cancer**, some **mouth and throat cancers**, and some cancers of the anal and genital areas. The current global COVID-19 pandemic threatens to derail the uptake of HPV vaccination in low- and lower-middle income countries, which has a major impact on the World Health Organization cervical cancer elimination strategy, which is dependent on HPV vaccination as well as cervical cancer screening and treatment. This Special Issue welcomes submissions across the broadest interpretation of these issues.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access:— free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com